Pharmaceutical Report Library l Report Store l Pharma Intelligence

Apleway

Apleway (tofogliflozin; Chugai) is a member of the novel sodium-glucose cotransporter-2 (SGLT-2) inhibitor class. SGLT-2 inhibitors do not target insulin secretion or sensitivity and do not interfere with glucose metabolism.

November 7, 2017

Find out more

Aplidin

Aplidin is an intravenous, marine-originated cyclic depsipeptide antitumor agent. The drug, which is

currently synthesized chemically, was originally isolated from the marine tunicate Aplidium albicans

(Cuadrado et al., 2003; PharmaMar, 2014).

September 4, 2014

Find out more

Aptiom

Aptiom is a once-daily oral drug containing eslicarbazepine acetate, a third-generation member of the commonly prescribed first-line dibenzazepine family of anti-epileptic drugs (AEDs), including carbamazepine (first-generation) and oxcarbazepine (second-generation).

May 23, 2017

Find out more

Aramchol

Aramchol (arachidyl amido cholanoic acid; Galmed) is a conjugate of cholic acid and arachidic acid, and belongs to the synthetic fatty acid bile acid conjugates (FABACs) family. Aramchol inhibits the liver enzyme stearoyl-CoA desaturase 1 inhibitor (SCD1), and as a result fatty acid synthesis is reduced while fatty acid oxidation is increased. Additionally, Aramchol has hypocholesterolemic effects due to the upregulation of ATP-binding cassette transporter 1 (ABCA1). Ultimately, Aramchol causes incomplete SCD inhibition while also being anti-atherogenic.

July 22, 2019

Find out more

Aranesp

Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human erythropoietin product administered by intravenous or subcutaneous injection, and is indicated for the treatment of anemia in chronic kidney disease and chemotherapy-induced anemia.

January 11, 2018

Find out more

Arcapta

Novartis has developed Arcapta (indacaterol; marketed as Onbrez outside the US) for use in its Breezhaler/Neohaler dry-powder inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

July 31, 2018

Find out more

Argentina Healthcare System Overview

$2,995.00

With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

November 3, 2016

Find out more

Argentina Regulatory Issues

$2,995.00

With a growing economy and 40 million inhabitants, Argentina is one of the most important emerging market destinations in South America.

November 2, 2016

Find out more

Aricept

Aricept (donepezil; Eisai/Pfizer) has been the gold standard in the treatment of all stages of
Alzheimer’s disease for more than a decade.

September 2, 2016

Find out more

Arikayce

Arikayce is a formulation of the antibiotic amikacin that uses Insmed’s liposomal delivery system and is under development for the treatment of lung infections caused by NTM.

September 3, 2018

Find out more

Aristada

Aristada (aripiprazole lauroxil; Alkermes) is a long-acting injectable formulation of the atypical antipsychotic aripiprazole. It was developed by Alkermes using its proprietary LinkeRx technology, which allows the gradual release of aripiprazole molecules and lowers the drug’s frequency of administration.

March 19, 2018

Find out more

Aromatase Resistance and Palbociclib for Breast Cancer

$89.00

These pathways can be targeted either at the cell surface receptor

level or their downstream signaling cascades. Currently, everolimus in combination with

exemestane represents a new standard of care for patients progressing on non-steroidal AIs.

HDAC inhibitors have also shown promising results For innate resistance, the combination of

fulvestrant and AI in the front line setting represents a new treatment option, particularly for

patients who present with de novo metastatic disease.

April 1, 2014

Find out more

Arthroscopy Products and Sports Medicine Fixation Implants (2021)

$4,750.00

This Meddevicetracker report provides an analysis of the market for arthroscopy products (including visualization systems, fluid management equipment, and manual and powered instruments) and sports medicine/soft tissue fixation implants for the US, five major EU markets, Japan, and the rest of the world.

March 18, 2021

Find out more

Arzerra

Arzerra (ofatumumab; Genmab/Novartis) is a fully human immunoglobulin G1 and high-affinity antibody that targets a novel epitope on cluster of differentiation 20 (CD20) on the B-cell membrane.

January 31, 2019

Find out more

Asciminib

Asciminib (Novartis) is a BCR-ABL-targeted tyrosine kinase inhibitor (TKI) in development by Novartis for Philadelphia chromosome-positive diseases such as chronic myeloid leukemia (CML) and acute lymphoblastic leukemia.

December 7, 2017

Find out more

Asia-Pacific Disease Incidence and Prevalence

$5,250.00

The Asia-Pacific (APAC) region is a part of the world which includes several developing and developed countries. Countries covered in this report include Australia, China, India, Japan, Malaysia, South Korea, Thailand, and Vietnam.

January 1, 2016

Find out more

Asia-Pacific: Surgical Procedure Volumes

$5,250.00

This report examines the healthcare trends in Asia-Pacific countries (Japan, China, South Korea, India, Thailand, Vietnam, Malaysia and Australia), as well as analyzes and forecasts (toward 2019).

September 1, 2015

Find out more

Aspirin

Aspirin (acetylsalicylic acid) is a non-steroidal anti-inflammatory drug (NSAID) and antiplatelet that is taken orally and commonly used for the treatment of pain. It is highly genericized and has been available in its present form since 1899, when it was first marketed by Bayer.

July 2, 2018

Find out more

Asthma and COPD KOL Interview

$599.00

KOL thinks that the biggest challenge to treating COPD is cost, even with a very low population of uninsured people.

February 29, 2016

Find out more

Asthma Pricing, Reimbursement, and Access

$2,995.00

The next wave of key therapies in asthma includes biologics, with interleukin (IL)-5 inhibitors first to reach the market.

October 17, 2016

Find out more

ATIR101

ATIR101 is an immunotherapeutic delivered as an adjunctive therapy for patients receiving HSCT.

July 6, 2017

Find out more

Atopic Dermatitis and Psoriasis KOL Interview – UK

$599.00

This interview with a UK-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Find out more

Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Find out more

Atopic Dermatitis and Psoriasis KOL Interview – US, South

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into their perception on unmet needs, JAK inhibitors, differentiation of IL-13 antibodies, prospects for topical drugs, as well as competitive positioning and access to biologics.

November 18, 2021

Find out more

Atrasentan

Atrasentan’s Phase III trial is unique including an enrichment period to select responders and those who tolerate the drug for randomization.

February 2, 2018

Find out more

Atripla

Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]; Gilead/Bristol-Myers Squibb) is a single-tablet regimen approved for the treatment of HIV-1 infection.

June 28, 2019

Find out more

Aubagio

Aubagio is the major active metabolite of Arava (leflunomide), Sanofi’s oral treatment for rheumatoid arthritis, and is a dihydroorotate dehydrogenase (DHODH) inhibitor.

November 24, 2017

Find out more

Aurora-GT

United Therapeutics is developing a gene therapy product called Aurora-GT (endothelial nitric oxide-synthase-enhanced endothelial progenitor cells)

October 29, 2018

Find out more

Auryxia

Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii Pharmaceutical) is a novel oral ferric iron form with hematinic activity, approved for the treatment of anemia in chronic kidney disease.

January 11, 2018

Find out more

Avastin

Avastin (bevacizumab; Roche/Chugai) is a humanized immunoglobulin G1 monoclonal antibody directed against vascular endothelial growth factor (VEGF).

February 26, 2020

Find out more

Avonex

Avonex is a biological therapy derived from the interferon family, and Biogen’s leading drug for treating relapsing-remitting multiple sclerosis (RRMS).

November 24, 2017

Find out more

Azeliragon

Azeliragon is an orally available small molecule that acts as an inhibitor of the receptor for advanced glycation endproducts (RAGE).

September 2, 2016

Find out more

Azilect

Azilect (Teva/Lundbeck/Takeda) contains the pure R-isomer of rasagiline and acts as a selective irreversible monoamine oxidase inhibitor (MAOI), with up to 10 times more potency than selegiline and without metabolizing into amphetamine derivatives.

June 21, 2018

Find out more

balixafortide

Balixafortide (Polyphor) is a synthetic cyclopeptide derived from polyphemusin that inhibits C-X-C motif chemokine receptor 4 (CXCR4), a G-protein coupled receptor that exclusively binds to its ligand, stromal cell-derived factor-1 (SDF-1).

February 26, 2020

Find out more

Banzel

Eisai’s Banzel is an oral sodium channel modulator which is structurally different from currently approved anticonvulsants on account of its triazole derivative structure. The drug’s sole approved indication is the adjunctive treatment of seizures…

May 23, 2017

Find out more

bardoxolone methyl

Bardoxolone methyl (AbbVie/Kyowa Hakko Kirin), under development by the research-stage company Reata Pharmaceuticals, is a Phase III candidate in clinical trials for the treatment of pulmonary arterial hypertension.

October 29, 2018

Find out more

baricitinib

Baricitinib is an oral reversible inhibitor of Janus kinase-1 (JAK1) and JAK2 – that is JAK3-sparing – under co-development by Incyte and Eli Lilly. It is currently in development for the treatment of inflammatory conditions including…

October 4, 2016

Find out more

Bavencio

Bavencio (avelumab; Merck KGaA/Pfizer) is a fully human MAb targeting the PD-L1 protein.

March 6, 2019

Find out more

Bax 817

BAX 817 is an rfVIIa therapy in development by Baxalta for patients with hemophilia A or B with inhibitors. FVIIa therapy can circumvent the need for fVIII and fIX in the coagulation cascade by directly activating factor X…

March 14, 2016

Find out more

Bay 94-9027

BAY 94-9027 (Bayer) is a long-acting recombinant factor VIII (rfVIII) product under development for the treatment of hemophilia A.

May 4, 2018

Find out more

bb2121

Pipeline product bb2121 (Celgene/bluebird bio) is a second-generation chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA), a promising target for immunotherapy which is found in 60–70% of multiple myeloma (MM) patients.

August 9, 2018

Find out more

Bempedoic Acid Franchise

Bempedoic acid is an orally administered small molecule that inhibits fatty acid and cholesterol synthesis.

November 20, 2019

Find out more

BeneFix

BeneFIX (Pfizer) is an recombinant factor IX (rfIX) therapy indicated for the control and prevention of bleeding in hemophilia B.

May 4, 2018

Find out more

Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market

$4,750.00

Symptomatic benign prostatic hyperplasia (BPH) and prostatitis affect more than 100 million men worldwide, lowering quality of life with painful symptoms that can be difficult to manage.

April 20, 2017

Find out more

Beraprost 314d

Beraprost (United Therapeutics/Astellas/Kaken Pharmaceutical Co) is an oral chemically stable prostacyclin analog targeting the prostaglandin I2 (PGI2) receptor…

June 19, 2015

Find out more

Report library

Apleway

Aplidin

Aptiom

Aramchol

Aranesp

Arcapta

Argentina Healthcare System Overview

Argentina Regulatory Issues

Aricept

Arikayce

Aristada

Aromatase Resistance and Palbociclib for Breast Cancer

Arthroscopy Products and Sports Medicine Fixation Implants (2021)

Arzerra

Asciminib

Asia-Pacific Disease Incidence and Prevalence

Asia-Pacific: Surgical Procedure Volumes

Aspirin

Asthma and COPD KOL Interview

Asthma Pricing, Reimbursement, and Access

ATIR101

Atopic Dermatitis and Psoriasis KOL Interview – UK

Atopic Dermatitis and Psoriasis KOL Interview – US, Northeast

Atopic Dermatitis and Psoriasis KOL Interview – US, South

Atrasentan

Atripla

Aubagio

Aurora-GT

Auryxia

Avastin

Avonex

Azeliragon

Azilect

balixafortide

Banzel

bardoxolone methyl

baricitinib

Bavencio

Bax 817

Bay 94-9027

bb2121

Bempedoic Acid Franchise

BeneFix

Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market

Beraprost 314d